P-19 Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)

P Merle,S Chica-Duque,T Zhang,B Li,M Bouattour,Jean Frédéric Blanc ,Éric Assenat ,Chia-Hung Yen ,Hong Pan ,Sheng Hu ,Lorenza Rimassa ,Peter Ross ,Gaoneng Shao ,Weijia Fang ,Alexia Tran ,Julien Edeline ,J Wu,Z Li,Y Chen,Zheng Ren

doi:10.1016/j.annonc.2022.04.110

P-19 Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)

P Merle, S Chica-Duque + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.04.110

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jun 1, 2022
License type: publisher-specific-oa

#Prior Lines Of Systemic Therapy #Tislelizumab In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tislelizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, showed clinical activity and was well tolerated in patients with previously treated advanced HCC in the phase 2 RATIONALE-208 study (NCT03419897). This analysis examined the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab.

Full Text